Download Free Medical About Guillain Barre Syndrome PowerPoint Presentation

About Guillain Barre Syndrome PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Due to the breadth of clinical presentation it is of limited help to try to define rigid diagnostic criteria.

Tags : guillain,syndrome,disease,guillain barre,influenza,vaccine

Published on : Mar 31, 2021 | Views : 3107 | Downloads : 6

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Guillain-Barre Syndrome William Woodfin MD
Slide 2-

K.F. 40 y.o. r/h woman 3/17 Nausea, diarrhea & severe myalgias Son dxed c rotavirus 1 wk. Previously 4/21 “Creepy-crawlies” legs>arms 4/25 Weakness legs progressing 4/26 Handwriting looks like “hen scratch”
Slide 3-

K.F. 40 y.o. woman 4/28 Admitted to outside hospital. L.P. wnl EMG positive waves in some leg muscles NCVs absent H-reflexes F responses & motor latencies wnl
Slide 4-

K.F. 40 y.o. woman 4/29 Transferred to PHD Hx.: diabetic x 10 yrs. hypothyroid- treatedx yrs. no sphincter disrubance aching pain low back & buttocks mild postural light headedness no SOB or palpatations
Slide 5-

Exam BP 150/90 P 80 Wt. 250 lbs. Mild weakness neck flexors 4/5 biceps, grip & interossei- symmetric 2/5 iliopsoas & quadriceps 3/5 hamstrings & adductors 4/5 abductors 4/5 ankles & toes- extensors & flexors
Slide 6-

Exam Sensory- intact DTRs- biceps, BR, knees are trace c reinforcement. Triceps & ankles unobtainable Plantars- flexor F to N- intact Gait- not testable
Slide 7-

Lab H/H 10.3/33.5 c microcytic indices A1c Hgb 10.1 TSH 0.97 LDL 182 Serum immunofixation- wnl. No IgA def. FVCs- consistently 4+ liters
Slide 8-

MRI LS spine s & c contrast- no nerve root enhancement
Slide 9-

Course in hospital Treated c IVIG 0.4 gms/kgm daily x 5 Strength fluctuated only mildly Blood sugars ok in AM, high in afternoons Repeated NCVs show mild dispersion of F waves Transferred back to referring hospital 5/6
Slide 10-

Telephone FU Ambulating fairly well c walker. Strength clearly improving. Still bothered by “creepy-crawlies”
Slide 11-

What is the GBS? Due to the breadth of clinical presentation it is of limited help to try to define rigid diagnostic criteria. Thomas Munsat 1965: “…The GBS is easy to diagnose but difficult to define
Slide 12-

The typical illness evolves over weeks usually following an infectious disease and involves: 1. Paresthesiaes usually hearld the disease 2. Fairly symmetric weakness in the legs, later the arms and, often, respiratory and facial muscles 3. Dimunition and loss of the DTRs 4. Albuminocytologic dissociation 5. Recovery over weeks to months
Slide 13-

History Waldrop 1834 Olliver 1837 Landry 1859 Graves 1884 Ross & Bury 1893 Brussel’s Conf. 1937 Haymaker & Kernohan 1949 Waksman & Adams 1955 Miller Fisher 1956 Asbury, Aranson & Adams 1969 Guillain, Barre & Strohl 1916-1920
Slide 14-

ppt slide no 14 content not found
Slide 15-

Note sur la paralysie ascendante aigue 1859 March 16- a febrile illness May 11- mild sensory symptoms in the fingers and toes June 13- knees buckle June 16- unable to walk Subsequent respiratory failure and death. Autopsy unrevealing. Peripheral nerves probably not examined
Slide 16-

Late 19th century Westphal 1876- “Landry’s Ascending Paralysis” Graves 1884- localized neurologic disease to the peripheral nerves, “the nervous cords” Ross & Bury 1893- 90 cases. A disease of the peripheral nerves Numerous reports emphasizing various aspects of the disease with most authors crediting Landry
Slide 17-

Georges Guillain
Slide 18-

Revue Neurologique 1916
Slide 19-

Guillain, Barre & Strohl 1916 Revue Neurologique Two soldiers in Amiens developing paralysis and loss of DTRs. A new diagnostic feature: albuminocytologic dissociation in the CSF No mention of Landry
Slide 20-

Foundations Quincke- CSF observations 25 years earlier Siccard & Foix- “albuminocytologic dissociation” in Pott’s disease Late 19th century: examination of the reflexes had become a part of the neurologic exam with appreciated as a sign of neuropathy based on observations in tabes dorsalis areflexia
Slide 21-

Haymaker & Kernohan 1949 Landmark in pathological description c 50 fatal cases & detailed review of clinical findings Emphasized prominent damage to proximal nerves often at junction of ventral & dorsal roots. Little study of more distal nerves Unified findings of Landry & Guillain, Barre & Strohl
Slide 22-

Waksman & Adams 1955 Experimental Allergic Neuritis First animal model of a noninfectious inflammatory neuritis Rabbit nerve and Freund’s adjuvant injected intradermally Target of activated T cells uncertain
Slide 23-

Asbury, Aranson & Adams 1969 19 pts. All with well developed mononuclear infiltrates in spinal roots and nerves within days of clinical onset Pathological hallmark: perivascular mononuclear inflammatory infiltrates to adjacent to the areas of demyelination
Slide 24-

Overview of Adaptive Immunity Lymphocytes: “command & control,” identify antigen components, respond specifically, mobilize other elements and direct the attack c memory for each antigenic assault Antibodies: specialized immunoglobulin molecules directly neutralize and remove antigen
Slide 25-

T lymphocytes CD8- recognize epitopes paired c MHC-I CD4- activate and control the immune response Scavenger cells break down antigen into small peptide fragments (T cell epitopes), MHC-II epitope complexes are expressed on the surface & the scavenger become an APC which docks on a CD4 c a compatible TCR. CD4 proliferates releasing cytokines.
Slide 26-

Antibodies Cytokines activate other lymphocytes including B cells that differentiate into plasma cells and serve as immunoglobulin factories. Abs are Ig molecules that recognize, bind, neutralize and opsonize Ag for phagocytosis. They activate complement(membrane attack complex) & induce target cells to activate the inflammatory response
Slide 27-

Cellular & Humoral Immune Mechanisms
Slide 28-

Self-tolerance The process of self recognition T & B cells learn self tolerance during maturation Autoimmunity occurs when the mechanisms of self protection are defective
Slide 29-

Mechanisms of Autoimmunity Molecular mimicry- microbe cell surface Ag resembles self protein. Damage results from “friendly fire” The inciting Ag is usually unidentified & may not exist as a single stimulus. Excessive cytokine release due to profound immune stimulus may awaken self tolerant T cells or may cause expression of MHC complexes. Self Ags bound to drugs may lose tolerated status
Slide 30-

Antecedent Events: Infectious Viral: Influenza, Coxsackie, EBV, Herpes, HIV, Hepatitis, CMV, WNV Bacterial: Campylobacter jejuni, Mycoplasma, E. coli Parasitic: Malaria, Toxoplasmosis
Slide 31-

Antecedent Events: Systemic disease Hodgkins CLL Hyperthyroidism Sarcoidosis Collagen Vascular d. Renal d.
Slide 32-

Other antecedent events Surgery Immunization Pregnancy Envenomization Bone marrow transplantation Drug ingestion
Slide 33-

Features of AIDP 2/3s have identifiable preceding event 50% begin with paresthesias followed by weakness in legs; 10% begin with arm weakness; rarely begins in face Ophthalmoplegia: partial 15%, total 5% Autonomic dysfunction in 65%, arrhythmias, hypotension,urinary retention in 10-15%, pupillary inequality
Slide 34-

AIDP Progresses for days to 4 weeks 15% with severe disability Mortality 3-5% CSF: protein may be normal early, elevated in 90% by clinical nadir, cells< 10 in 95%, >50 suggests HIV EDX: prolonged F & distal motor latencies, conduction block 30-40% in routine studies
Slide 35-

AIDP Pathology: immune attack directed at schwann cell plasmalemma esp. at nerve roots with IgG & complement deposits preceding demyelination
Slide 36-

ppt slide no 36 content not found
Slide 37-

CIDP Evolves over months Fluctuates Respiratory failure, dysautonomia, facial weakness, ophthalmoplegia- all are rare CSF protein often highly elevated Marked slowing of motor nerve conduction Steroid responsive
Slide 38-

Features of AMSAN Commonly preceded by diarrhea esp. c. jejuni Abrupt onset of weakness c rapid progression to quadriplegia & respiratory insufficiency Other features as c AIDP Longer recovery, more residual & mortality 10-15%
Slide 39-

AMSAN CSF as in AIDP EDX: no response in some motor nerves, decreased amplitude of the CMAPs, fibrillations on needle study, absent SNAPs Immune attack directed at axon plasmalemma at nodes of Ranvier. Wallerian degeneration
Slide 40-

Features of AMAN Often preceded by diarrhea affecting younger population in China. Sporadic in USA Prognosis similair to AIDP Mortality <5% EDX: reduced CMAPs c normal F & distal motor latencies and sensory studies. Fibrillations in 2-3 weeks
Slide 41-

AMAN Pathology: again axonal plasmalemma at nodes of Ranvier sometimes limited to physiologic dysfunction c nodal lengthening. May go on to extension through axonal basal lamina. Most axons recover s Wallerian degeneration
Slide 42-

ppt slide no 42 content not found
Slide 43-

Miller Fisher Syndrome Ophthalmoplegia, Ataxia, Areflexia May be heterogonous: 1. Related to other patterns of GBS 2. Related to brainstem encephalitis, Bickerstaff 1952 3. CNS demyelination in association with GBS
Slide 44-

Miller Fisher Syndrome 95% have serum IgG Ab to ganglioside GQ1b Studies show preferential location of anti-GQ1b to cerebellar molecular layer & Cranial Nerves 3,4 & 6 May act at N-M junction depleting acetylcholine from nerve terminals
Slide 45-

Acute Panautonomic Neuropathy Manifests over 1-2 weeks but may be of subacute onset Frequent preceding infection DTRs lost in 1/3, distal sensory changes 1/4 Albuminocytologic dissociation EDX: NCVs usually normal Recovery is gradual and incomplete
Slide 46-

Differential Diagnosis Consider the possibility of an upper motor neuron lesion Other considerations are rare. Diphtheritic neuritis & poliomyelitis belong more to the history section of this presentation. A new possibility is West Nile Virus.
Slide 47-

Differential N-M: MG, LES, Antibiotics Toxic: Cigutera (ciguatoxin), Pufferfish (tetrodotoxin), Shellfish (saxitioxin), Botulism, Tick paralysis (Lone Star tick, Gulf Coast tick), Glue sniffing, Buckthorn Mononeuritis multiplex assoc. c Wegner’s. PAN, SLE, RA, Sjogren’s, Cryoglobulinemia etc.
Slide 48-

Differential Metabolic: Periodic paralyses, Hypokalemia, Hypermagnesemia, Hypophoshatemia c parenteral hyperailimentation, Thyrotoxicosis, ICU myoneuropathy (CIP) Heavy metal: Lead, Arsenic, Thallium, Barium c hypokalemia
Slide 49-

Differential: Miller Fisher Syn. Multiple sclerosis Encephalitis Posterior circulation ischemia or infarct Other: Botulism, MG, Tick
Slide 50-

Treatment Respiratory failure Autonomic dysfunction DVT & PE Pain Positioning & Skin care Physical therapy Nutrition
Slide 51-

Respiratory Failure Oropharyngeal weakness in ~25% with impaired swallowing of secretions & aspiration Mechanical respiratory failure- mainly due to diaphragmatic weakness (Phrenic nerves.) Inspiratory c MIF (Max. Inspir. Force) a good supplement measure to FVC
Slide 52-

Respiratory Failure ~33% require intubation Avg. time to intubation is 1 week & these pts. have substantially longer recovery time Need is unlikely if patient does well for 2 wks. post onset of paresthesiaes Guidelines: FVC <15 mL/kgm MIF < 25 cm water
Slide 53-

Psychological Fear Helplessness Communication Pain Sleep deprivation & hallucinosis Depression Visits from other GBS patients
Slide 54-

Personal Experience Bowes, Denise; The doctor as patient: an encounter with Guillain-Barre syndrome. Can Med Assoc J 131:1343-1348
Slide 55-

Corticosteroids Lancet 1993 242 pts. IV Methylprednisilone 500 mgm/day x 5. Ineffective May cause relapse
Slide 56-

Plasma Exchange Removal of the blood’s liquid soluble components including complement, immunoglobulin, immune complexes, cytokines and interleukins A typical session removes about 60% of the body mass of plasma proteins which is replaced c saline, albumin & FFP Done qod for 3-5 sessions
Slide 57-

Plasma Exchange Various studies since 1985 Time on ventilator reduced by ½ Full strength regained at 1 year: Exchange 71%, Untreated 52% Limitations: Limited availability Avoid with autonomic instability
Slide 58-

Intravenous Immune Globulin Originally used for immune insufficiency Use as an immunosuppresant “seems to defy reason” 1981 Rx for ITP 5,000-10,000 donors/batch. Diversity of Abs from large donor pool maximizes effect
Slide 59-

IVIG Mechanism of action- unknown ? Antiidiotypic antibody action ? Inhibition of cytokines ? “Sponging” of complement ? Binding to Fc receptors so macrophages can’t bind
Slide 60-

IVIG Dosage: 0.4 gms/kgm/day x 5 c each dose given over 3-4 hours preceded by IV diphenhydramine &/or po ibuprofen Caution c renal insufficiency or IgA deficiency 38 Center trial in 1997 Equal to plasma exchange
Slide 61-

J.H.C. 48 yo welder June ’02 H.A. followed in 2 wks by Lt. Facial weakness June ’03 Rhinorrhea & cough August 6 Pain lt. Hip spreading over a few days to back 7 legs August 15 Legs buckle c lt.facial weakness 1 wk later. LP c protein of 70. NCVs c prolonged F waves
Slide 62-

1 Week post discharge, elevated titers to West Nile Virus Follow up at 1 month- continued improvement

User Presentation
Related Presentations

How did the Indian Pharmaceutical Market Become Self-Sufficient

By: anupma
Views: 964

Acceleration of Biopharma Partnering Activity Into China

By: anupma
Views: 1294

Recent Trends in Oncology Business Development

By: anupma
Views: 1485

Pharmacy Handbook to Compliance

By: anupma
Views: 1090

Global pharma and Indian pharmaceutical industry: Prospects for growth

By: anupma
Views: 958

What are the types causes and treatment of phobia

By: rainbowstart
Views: 577

Thyroid Emergencies

By: KhushbuSG
Views: 732

Human Immunodeficiency Virus

By: Abbyabby22
Views: 765

Addiction and Drug Abuse

By: yourdoctors
Views: 1220

Communication

By: Nick19
Views: 2200

anupma

About : A Healthcare MarCom professional...I have experience on managing healthcare marketing communication online...on website, social media and off course email.
Occupation : Health Enthusiast
Specialty : Health Enthusiast
Country : India
Website : https://www.medicpresents.com

HEALTH A TO Z